Recombinant Protein Therapeutics CDMO Market – Type (Oncology Agents, Insulin, Interferon, Vaccine), Source (Mammalian, E. coli), Therapeutic Area (Oncology, Immunological, Metabolic Disorders), Service Type, End-user, Global Forecast (2024 – 2032)
Recombinant protein therapeutics CDMO market size is anticipated to record 14% CAGR between 2024 and 2032, driven by the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders. As per WHO, in 2022, there were 20 million new cancer cases followed by 9.7 million deaths worldwide. Pharmaceutical companies are turning to private CDMOs for manufacturing solutions as they develop new biologics to meet medical needs.
The biopharmaceutical sector is growing due to biotechnology advancements and investments in research. CDMOs offer expertise and infrastructure to accelerate drug development and reduce manufacturing risks for companies. The increasing demand for personalized and targeted medicine is also driving the need for specialized manufacturing services from CDMOs, leading to market growth.
The overall industry is segmented into type, source, therapeutic area, service type, end-user, and region.
Recombinant protein therapeutics CDMO market from the vaccines type segment will gain significant traction during 2024-2032. The global demand for vaccines has surged due to the COVID-19 pandemic, further prompting the development of antiviral vaccines. Pharmaceutical companies are turning to specialized CDMOs with expertise in vaccine production to meet the increasing need. CDMOs also help in accelerating vaccine production due to the complex process, strict regulations, and increasing demand for vaccines worldwide.
By therapeutic area, the recombinant protein therapeutics CDMO industry from the haematological disorders segment is anticipated to witness notable CAGR from 2024 to 2032. The rise in blood diseases like leukemia, lymphoma, and hemophilia is necessitating the development of advanced biologics, like protein grafting medications for better treatment. Pharmaceutical and biotech firms are concentrating on developing new therapies for blood disorders, shifting to specialized CDMOs for synthetic protein production expertise due to complex manufacturing processes and strict quality control requirements.
Asia Pacific recombinant protein therapeutics CDMO market is anticipated to witness sustained growth during 2024-2032. Recombinant protein therapeutics are gaining traction in the region for offering cost-effective alternatives to expensive biologics. Moreover, there has been an increasing demand for biologics, advancements in technology, and supportive government policies. This presents a significant opportunity for CDMOs specializing in biopharmaceutical manufacturing to expand their presence and cater to the growing needs of the region.
- Chapter 1 Methodology & Scope
- 1.1 Market scope & definitions
- 1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
- 1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
- 1.4 Forecast model
- 1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources
- Chapter 2 Executive Summary
- 2.1 Industry 360 degree synopsis
- Chapter 3 Industry Insights
- 3.1 Industry ecosystem analysis
- 3.2 Industry impact forces
- 3.2.1 Growth drivers
- 3.2.1.1 Increasing demand for biologics
- 3.2.1.2 Rising adoption of CDMOs for outsourcing manufacturing activities
- 3.2.1.3 Rising investmnets in R&D
- 3.2.2 Industry pitfalls & challenges
- 3.2.2.1 High cost of manufacturing
- 3.2.2.2 Quality control challenges
- 3.3 Growth potential analysis
- 3.4 Regulatory landscape
- 3.5 Porter's analysis
- 3.6 PESTEL analysis
- Chapter 4 Competitive Landscape, 2023
- 4.1 Introduction
- 4.2 Company matrix analysis
- 4.3 Competitive analysis of major market players
- 4.4 Competitive positioning matrix
- 4.5 Strategy dashboard
- Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)
- 5.1 Key trends
- 5.2 Oncology agents
- 5.3 Insulins
- 5.4 Immunostimulating and immunosuppressive agents
- 5.5 Autoimmune
- 5.6 Interferons
- 5.7 Vaccines
- 5.8 Blood coagulation factors
- 5.9 Growth hormones
- 5.10 Other types
- Chapter 6 Market Estimates and Forecast, By Source, 2021 - 2032 ($ Mn)
- 6.1 Key trends
- 6.2 Mammalian
- 6.3 E. coli
- 6.4 S. cerevisiae
- 6.5 Other sources
- Chapter 7 Market Estimates and Forecast, By Therapeutic Area, 2021 - 2032 ($ Mn)
- 7.1 Key trends
- 7.2 Oncology
- 7.3 Metabolic disorders
- 7.4 Immunological disorders
- 7.5 Infectious diseases
- 7.6 Hematological disorders
- 7.7 Women health
- 7.8 Other therapeutic areas
- Chapter 8 Market Estimates and Forecast, By Service Type, 2021 - 2032 ($ Mn)
- 8.1 Key trends
- 8.2 Contract manufacturing
- 8.3 Contract development
- Chapter 9 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)
- 9.1 Key trends
- 9.2 Pharmaceutical companies
- 9.3 Biotechnology companies
- 9.4 Other end-users
- Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)
- 10.1 Key trends
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Rest of Europe
- 10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 Rest of Asia Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest of Latin America
- 10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 Rest of Middle East and Africa
- Chapter 11 Company Profiles
- 11.1 Batavia Biosciences B.V.
- 11.2 BIOVIAN
- 11.3 Catalent, Inc
- 11.4 Curia Global, Inc.
- 11.5 Enzene Biosciences Ltd
- 11.6 FUJIFILM Diosynth Biotechnologies
- 11.7 HALIX B.V.
- 11.8 Lonza
- 11.9 Richter-Helm BioLogics
- 11.10 WuXi Biologics
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook